CCCA: Central Centrifugal Cicatricial Alopecia

Central centrifugal cicatricial alopecia, almost always abbreviated CCCA, is the most common form of scarring hair loss in Black women in the United States. It begins as a small area of thinning at the vertex of the scalp and expands outward over years. By the time the change is obvious in a mirror, the underlying follicles in the central patch may already be replaced by scar tissue, which is permanent. Because of that, CCCA is one of the few hair-loss diagnoses where time to evaluation directly determines what is recoverable.

This page covers what CCCA is, how it presents, why it requires in-person dermatologic evaluation rather than telehealth-only care, what testing and treatment usually involve, and when a soft scalp symptom is worth taking to a specialist now rather than waiting.

What CCCA is

CCCA belongs to a family of conditions called scarring or cicatricial alopecias. In these disorders, sustained inflammation around the follicle destroys the stem cells responsible for regeneration. The follicle is gradually replaced with fibrous tissue, the small pore on the scalp through which the hair once emerged disappears, and no medication regrows hair in that spot (Olsen EA et al., J Am Acad Dermatol, 2011). This is the opposite of androgenetic alopecia, where the follicle miniaturizes but persists, and where medical treatment can reactivate it.

CCCA is "central" because it starts at the vertex (the crown), and "centrifugal" because it spreads outward in roughly concentric rings. Early on, the affected area may be the size of a coin. Without treatment, it can expand to a palm-sized patch over years.

Who it affects

CCCA disproportionately affects women of African descent, particularly Black women in the United States. Estimates vary, but population studies and dermatology clinic data suggest prevalence is meaningful: one Cleveland Clinic series identified CCCA in roughly 6 percent of Black women undergoing dermatologic evaluation for any reason (Kyei A et al., Arch Dermatol, 2011). Men and women of other backgrounds are occasionally affected, but the diagnosis is uncommon outside the population where it was first described.

Two biological associations have been clarified in recent years. First, mutations in the PADI3 gene, which encodes a protein critical for the hair shaft, are present in a meaningful subset of CCCA patients (Malki L et al., N Engl J Med, 2019). This finding supports the idea that genetic susceptibility, not styling alone, sets the stage for the disease. Second, CCCA appears to be associated with type 2 diabetes and with uterine leiomyomas (fibroids), suggesting a shared inflammatory or fibrotic biology that goes beyond the scalp (Dina Y et al., JAMA Dermatol, 2018).

The historical label "hot comb alopecia" used in the 1960s linked CCCA to thermal styling, and contemporary research has examined chemical relaxers, traction styling, and other grooming exposures. The most current view is that these may contribute to inflammation in genetically susceptible patients but are not sufficient causes on their own. Many women with extensive heat or chemical exposure never develop CCCA, and many with CCCA have minimal exposure history.

How it presents

CCCA can be silent or symptomatic. The most useful early signs are:

• Gradual widening of the part at the crown
• A small patch of reduced density at the vertex that does not recover with shorter, looser styling
• Tenderness, itching, burning, tingling, or a "pins and needles" sensation localized to the crown
• A scalp that feels smooth or shiny in the affected area
• Loss of the regular pattern of small dots (follicular openings) when the scalp is examined under magnification, which is one of the things a dermatologist looks for during trichoscopy

A meaningful share of women have minimal symptoms until thinning is already visible. The absence of pain or itch does not mean the process is inactive.

Why this requires in-person dermatology

Most pattern hair loss can be assessed safely through telehealth: a clinician reviews photographs and history, recognizes the typical pattern, and recommends standard medications. CCCA is different in several specific ways:

1. The diagnosis often requires a scalp biopsy. A small punch biopsy taken from the edge of the affected area shows the characteristic inflammation and follicular dropout. Telehealth cannot perform a biopsy, and without one, CCCA can be confused with androgenetic alopecia, traction alopecia, or other scarring alopecias that would be managed differently.

2. The treatment is not what is prescribed in pattern hair loss. Standard pattern-baldness medications (minoxidil, finasteride, dutasteride, spironolactone) are not the cornerstone of CCCA care. The mainstays are anti-inflammatory therapies: high-potency topical corticosteroids, intralesional steroid injections delivered into the scalp at intervals, oral doxycycline at sub-antibiotic anti-inflammatory doses, and, for more aggressive disease, hydroxychloroquine or other immunomodulators. Minoxidil may be used as an adjunct to help any remaining non-scarred follicles, but it does not treat the underlying disease.

3. Disease activity must be monitored over months and years. A dermatologist examines the scalp serially to decide whether inflammation has been suppressed enough to taper therapy. That clinical judgment, including hands-on trichoscopy and palpation, is not well served by photograph-based reviews alone.

4. Misdiagnosis has real cost. Treating CCCA as if it were pattern hair loss delays anti-inflammatory therapy. Every month of unchecked inflammation is more follicles transitioning from "still alive" to "scarred and permanent."

For these reasons, Curekey's clinicians, like most telehealth physicians who handle hair-loss assessments, refer suspected scarring alopecia to in-person dermatology for diagnosis and primary management. We can sometimes play a supportive role afterward, particularly when adjunctive medical therapy is indicated for adjacent pattern thinning, but the primary care of CCCA is dermatologic and in person.

What in-person evaluation usually involves

A first dermatology visit for suspected CCCA typically includes:

• A history of how the thinning began, its pattern of spread, and any associated scalp symptoms
• A history of grooming practices, not as a way to assign cause but to identify modifiable contributors
• Trichoscopy: a magnified examination of the scalp with a dermatoscope to look for loss of follicular openings, peripilar (around the hair) inflammation, and other patterns specific to scarring alopecias
• A 4 mm punch biopsy from the edge of the affected area, processed for both vertical and horizontal sections so the pathologist can count miniaturized, scarred, and intact follicles
• Discussion of treatment intensity based on disease activity, symptoms, and how much loss has already occurred

Lab work (a CBC, fasting glucose, hemoglobin A1c, and sometimes other studies) may be ordered given the recognized associations with diabetes and other inflammatory conditions.

What treatment aims to do

The goal of CCCA treatment is to stop active inflammation, not to regrow hair that has already been replaced by scar. When inflammation is suppressed early, the disease can be held stable for years and the patient retains what they have. When inflammation is left to run, the same medications applied later have less and less to work with.

Typical components include:

• High-potency topical corticosteroid applied to the affected scalp, often daily during active disease
• Intralesional triamcinolone injected into the inflamed peripheral zone every 4 to 8 weeks
• Doxycycline 50 to 100 mg daily for its anti-inflammatory rather than antibiotic effect
• Hydroxychloroquine for patients with more aggressive or refractory disease
• Adjunctive topical minoxidil to support any preserved follicles, though it is not the primary therapy
• Styling guidance that minimizes chemical and thermal exposure, in coordination with a stylist familiar with hair care for women with scarring alopecia

Surgical hair restoration is sometimes considered after the disease has been demonstrably inactive for at least one to two years, since transplanting into an actively inflamed scalp risks losing the grafted follicles to the same process.

When to seek evaluation

If any of the following apply, an in-person dermatology evaluation is worth scheduling now rather than later:

• A patch of thinning at the crown that has appeared or expanded over months
• Persistent itching, burning, tenderness, or pins-and-needles sensation localized to the crown
• A scalp that feels smooth or shiny in the affected area, or where the part has widened in a specific spot
• A family member who has been diagnosed with CCCA
• A diagnosis of type 2 diabetes alongside new crown thinning

The earlier the disease is identified, the more meaningful intervention is. There is no clinical reason to wait until the thinning is obvious in photographs.

Finding a dermatologist with specific experience in scarring alopecia in skin of color is worthwhile. The American Academy of Dermatology, Skin of Color Society, and major academic dermatology departments maintain directories that can help locate a clinician with the right training.

How CCCA is distinguished from other diagnoses

Several conditions can produce thinning at the crown and require different treatment:

• Androgenetic alopecia (pattern hair loss): more diffuse thinning, no loss of follicular openings, no scarring on biopsy.
• Traction alopecia: hair loss from chronic styling tension, typically at the temples and hairline rather than the crown.
• Frontal fibrosing alopecia: a different scarring alopecia that involves the frontal hairline and, often, the eyebrows.
• Telogen effluvium: diffuse shedding triggered by illness, stress, or medication, without focal crown loss.
• Alopecia areata: autoimmune patchy loss with well-demarcated borders and preserved follicular openings.

Biopsy is the single most decisive test when the picture is not clear from clinical examination alone.

Considering medical assessment

CCCA is a condition where the right next step is often not telehealth. Curekey is a HIPAA-compliant platform where licensed U.S. physicians review each case, and our standard process is to flag suspected scarring alopecia for in-person dermatologic care. For women with adjacent pattern thinning or other concerns that fall within the scope of telehealth, we can help with the medical pieces that fit. For the disease itself, an in-person dermatologist remains the primary clinician.

If you are unsure where your situation falls, the how it works page describes our assessment process, and an initial review can clarify whether your case is one we can support directly or one we will route to in-person care.

Related reading

• Hair loss overview: the pillar covering causes, patterns, and treatment options.
• Women and hair loss: hormonal, medical, and life-stage contributors to female hair thinning.
• Traction alopecia: a related diagnosis often confused with early CCCA at the hairline.
• Androgenetic alopecia explained: the most common form of pattern hair loss.
• Crown thinning: the broader category of vertex loss, which includes both pattern and scarring causes.
• Glossary of hair loss terms: definitions for cicatricial alopecia, trichoscopy, follicle miniaturization, and related references.
• How Curekey works: clinical assessment process and what to expect.

Key references

• Olsen EA et al. J Am Acad Dermatol, 2011. Central scalp alopecia photographic scale in African American women.
• Kyei A et al. Arch Dermatol, 2011. Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia.
• Malki L et al. N Engl J Med, 2019. Variant PADI3 in central centrifugal cicatricial alopecia.
• Dina Y et al. JAMA Dermatol, 2018. Association of uterine leiomyomas with central centrifugal cicatricial alopecia.